Zhejiang Xinguang Pharmaceutical Co. Ltd. Class A

Zhejiang Xinguang Pharmaceutical Co. Ltd. Class A

SSZSE:300519
13.94
CNY
-0.41
(-2.86%)
0.45EPS
32.74P/E
2.37BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.24
2.43
2.6
2.36
1.93
1.73
1.83
1.77
1.99
2.2
1.68
1.65
1.66
1.68
Basic EPS, GAAP
0.6
0.88
0.99
0.89
0.66
0.55
0.59
0.62
0.71
0.68
0.4
0.31
0.34
0.45
Free Cash Flow per Basic Share
0.42
0.65
0.92
0.74
0.58
0.45
0.52
0.64
0.79
0.69
0.23
0.3
0.41
- -
Dividend per Share
0.11
0.5
0.5
- -
0.25
0.25
0.3
0.45
0.6
0.6
0.5
0.39
0.3
- -
Book Value per Share
1.68
2.07
2.58
4
4.41
4.71
5
5.17
5.29
5.37
5.28
5.19
5.23
5.34
Tangible Book Value per Share
1.59
1.99
2.49
3.94
4.35
4.65
4.92
5.1
5.22
5.31
5.22
5.14
5.18
5.29
Basic Weighted Avg Shares
120
120
120
134
161
160
159
160
161
160
161
163
159
161
Sales/Revenue/Turnover
268
292
311
315
311
276
291
283
321
351
270
268
265
271
Operating Margin (%)
30.79
40.59
43.27
41.26
37.41
31.45
32.1
33.03
34.51
32.19
18.96
12.84
18.22
28.21
Depreciation Expense
6
6
6
6
6
8
10
13
13
14
15
15
15
- -
Net Income, GAAP
72
106
119
119
106
88
94
99
114
109
64
50
54
73
Effective Tax Rate (%)
14.19
14.07
13.93
14.13
13.36
12.75
13.27
13.78
13.4
13.36
12.03
11.61
14.53
12.73
Profit Margin (%)
27.05
36.17
38.14
37.73
34.15
31.85
32.24
34.96
35.62
30.96
23.8
18.83
20.43
26.96
Working Capital
123
155
204
522
565
604
648
691
711
724
708
704
723
755
LT Debt
2
2
2
2
2
2
2
- -
- -
- -
- -
- -
- -
- -
Total Equity
202
249
309
640
706
753
800
827
846
859
844
831
837
854
Return on Invested Capital (%)
36.36
43.61
40.34
23.26
15.52
11.95
12.03
11.82
13.6
12.65
7.56
6.03
6.6
8.78
Return on Capital (%)
39.12
45.99
42.06
24.91
15.72
11.33
12.06
12.15
11.94
12.76
7.56
6.02
6.5
8.75
Return on Common Equity (%)
42.18
46.86
42.55
25.05
15.77
12.06
12.09
12.17
13.66
12.76
7.56
6.02
6.5
8.75

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
160
160
160
Market Capitalization
2,462
1,896
2,371

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
808
774
803
Cash, Cash Equivalents & STI
772
732
749
Accounts Receivable, Net
7
11
16
Inventories
26
29
35
Total Current Liabilities
49
46
49
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.48%
0.25%
0.76%
Free Cash Flow
1.01%
1.94%
35.69%
Net Income, GAAP
-5.99%
-8.86%
7.58%
Sales/Revenue/Turnover
-1.07%
-0.41%
-0.86%
Total Cash Common Dividend
- -
- -
-25%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
101
46
70
51
268
2025
93
48
- -
60
265
2026
88
54
68
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.02
0.08
0.08
0.31
2025
0.15
0.05
- -
0.06
0.34
2026
0.16
0.08
0.15
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.39
2025
- -
- -
- -
- -
0.3
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yue Jun Wang
Full Time Employees
309
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 25, Huancheng West Road Shengzhou ZH China 312400
IPO Date
Jun 24, 2016
Business
Zhejiang Xinguang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical products, including Chinese patent medicines, chemical medicines, and health food. Its main product categories consist of Chinese patent medicines particularly focused on vascular and trauma diseases; chemical medicines; health food products; and pharmaceutical formulations targeting respiratory, digestive, urinary, pediatric diseases, and immune system enhancement. Prominent products include astragalus extract, stretchant capsules, American ginseng oral solutions, astragalus granules, and supplemental granules. The company targets primarily the Chinese market, with operations headquartered in Shengzhou, China, and was founded in 1998. In the past 1-2 years, Zhejiang Xinguang Pharmaceutical has engaged in strategic expansions including new product launches related to health foods and Chinese patent medicine formulations. Although specific recent acquisitions or partnerships have not been explicitly detailed in public disclosures, the company's operational focus remains centered on expanding its portfolio of proprietary Chinese medicines and chemical drug products. The firm has maintained a strong market presence in China with sustained R&D investment to develop cardiovascular and trauma-related pharmaceutical products. The company is listed on the Shenzhen Stock Exchange (Ticker: 300519.SZ) and continues to emphasize its role within the pharmaceutical and health food industry sectors in China. Its business strategy involves sustainable growth through innovative product development and enhancing its existing product lines in traditional Chinese medicine and chemical pharmaceuticals. Zhejiang Xinguang Pharmaceutical employs over 300 personnel and maintains manufacturing and distribution capabilities mainly within the Chinese domestic market. Overall, Zhejiang Xinguang Pharmaceutical Co., Ltd. operates as a comprehensive pharmaceutical enterprise focusing on traditional Chinese medicine and chemical pharmaceuticals, with recent strategic priorities on expanding product offerings and reinforcing its domestic market footprint. The company’s headquarters is located in Shengzhou, Zhejiang Province. This description reflects its current product portfolio and operational focus along with recent strategic developments as publicly disclosed up to 2025.